The 7investing.com Podcast 4n5m

Lemonade (NYSE: LMND) is a new player who's really adding zest to the insurance industry. Its AI-powered underwriting enables it to write new policies much more efficiently than its less-tech-savvy traditional competitors.And in addition to its agent-related costs being a fraction of others, its unique Synthetic Agents marketing approach is providing a very lucrative LTV/CAC of 3X (which is very good).In this 7investing exclusive livestream event, I shared a formal presentation that included insights about Lemonade's fundamental results, key metrics, competitive differentiation, current valuation, and technical trading factors that might make this stock particularly intriguing.It was also an interactive event, with a real-time chat and questions in the Q&A. I enjoyed this refreshing event, where we found out whether Lemonade is worth the squeeze as an investment. Thank you to all who attended live!

The digital advertising industry is, in many ways, a bellwether of the American economy. It's a direct look at how and where companies are acquiring new customers, as well as how things are going in the business world. PubMatic (Nasdaq: PUBM) is one of the digital advertising industry's earliest trailblazers. Founded in 2006, its mission has always been to provide a platform for PUBlishers to autoMATICally monetize their websites, podcasts, and streaming TV channels with programmatic ads. In the future, that might expand to new formats like VR headsets or even self-driving cars. 7investing recently sat down with PubMatic founder & CEO Rajeev Goel to discuss how he sees the digital ad industry evolving. Here's a look at the topics we discussed: 1) Industry overview (0:00): Where does digital advertising stand in 2025? 2) Competitive advantage (4:45): What are PubMatic's structural sources of competitive advantage, especially compared to your peers? 3) The Next Big Thing (13:32) : Header bidding for CTV in 2020, then Connect in 2022, then Activate in 2023. What's your next major growth format? 4) Connected TV (18:26) : Streaming ads seem more interactive now. How is CTV evolving? 5) Supply Path Optimization (22:32) : SPO is still 55% of total activity yet DBRR fell during Q1. Have the large publishers now fully consolidated their inventory? 6) The Trade Desk (26:02): The Trade Desk continues to promote OpenPath and says it will disrupt the industry. How do you believe OpenPath will most likely impact PubMatic? 7) The Macro (33:24): Several forecasts are reducing expectations for ad budgets in 2025. What are you seeing on the near-term horizon? 8) Capital Allocation (37:46): Just announced a $100m buyback expansion. How are you prioritizing capital allocation to maximize shareholder value? Are you ready to begin investing in your future? 7investing today at 7investing.com/subscribe and get your first 7 days absolutely free!

Today's 7investing podcast is all about Rocket Lab! The space economy is hitting an inflection point. And that will be good news for its earliest investors. Eastern European conflicts, standoffs between China and Taiwan, and new commercial interests are creating a trillion-dollar industry in Earth’s orbit. And this is much more than just glorified media hype. An unprecedented number of applications is forcing the FCC to streamline its review process, as the number of active satellites is growing incredibly quickly. Rocket Lab (NASDAQ: RKLB) is in the perfect position to benefit. This small-cap, small-launch provider’s revenues will skyrocket during the next decade, while also dramatically reducing its costs due to the reusability of its rockets. Its rocket scientist CEO Peter Beck is a New Zealand gem, not afraid to get his hands dirty and don the hard hat to build bigger rockets and serve more demanding customers. Credibility and long-term relationships are vitally important in the launch industry. Rocket Lab is gaining both…at an accelerating pace. The Solar System is the limit for this disruptor. Rocket Lab is a very high risk investment who faces a myriad of challenges, but is also growing quickly in a massive and mostly unexplored new market. It’s time to place another bet on the Final Frontier.

Today's 7investing podcast is all about Rocket Lab!The space economy is hitting an inflection point. And that will be good news for its earliest investors.Eastern European conflicts, standoffs between China and Taiwan, and new commercial interests are creating a trillion-dollar industry in Earth’s orbit. And this is much more than just glorified media hype. An unprecedented number of applications is forcing the FCC to streamline its review process, as the number of active satellites is growing incredibly quickly.Rocket Lab (NASDAQ: RKLB) is in the perfect position to benefit. This small-cap, small-launch provider’s revenues will skyrocket during the next decade, while also dramatically reducing its costs due to the reusability of its rockets.Its rocket scientist CEO Peter Beck is a New Zealand gem, not afraid to get his hands dirty and don the hard hat to build bigger rockets and serve more demanding customers. Credibility and long-term relationships are vitally important in the launch industry. Rocket Lab is gaining both…at an accelerating pace.The Solar System is the limit for this disruptor. Rocket Lab is a very high risk investment who faces a myriad of challenges, but is also growing quickly in a massive and mostly unexplored new market. It’s time to place another bet on the Final Frontier.To have the presentation emailed to you directly (which will publish on the morning of May 14th), please sign up for our email list at 7investing.com/newsletter.

Three Catalysts that Could Send Crocs' Stock SoaringOriginally recorded: May 9, 2025Some great investment opportunities are sexy tech companies that are growing quickly and everyone is familiar with. But others can be boring shoe companies, who are growing slowly and yet are ridiculously profitable.Crocs (Nasdaq: CROX) is an example of the latter. Stuck between the uncertainties of a recession, slowing consumer spending, and a trade war, CROX is now selling for just 7x its trailing earnings. That's very cheap; a clear sign the market is putting these shares on the bargain rack.But Simon has found three hidden catalysts that he believes could drive the price of this small-cap significantly higher. He discussed them on today's 7investing podcast. This show is sponsored by Prophet. Prophet's AI engine incorporates fundamental and technical analysis to make stock recommendations every month. With an outstanding track record over 16 years, it's the perfect tool for ive investors who want actionable ideas but don't have a lot of time.Through 7investing's exclusive partnership, new can get a $50 discount and also the first two months free by visiting ⁠https://www.useprophet.com/7investing⁠But hurry: this no-upfront-cost deal is only available until July 7th!

Palantir and Upstart: Soaring Growth but Falling Stock Prices Originally recorded: May 7, 2025 Palantir Technologies (Nasdaq: PLTR) and Upstart Holdings (Nasdaq: UPST) are two of the market's hottest stocks. Both are using AI to enhance their intelligent platforms and are seeing their top-line growth accelerate. Yet curiously, even after reporting excellent quarterly results, both stocks are selling off significantly. Are there hidden risks that investors are becoming more worried about? Or have the baked-in expectations simply gotten too high? Simon digs into both companies on today's 7nvesting podcast. As a perfect fit for an episode about AI, this show is sponsored by Prophet. Prophet's AI engine incorporates fundamental and technical analysis to make stock recommendations every month. With an outstanding track record over 16 years, it's the perfect tool for ive investors who want actionable ideas but don't have a lot of time. Through 7investing's exclusive partnership, new can get a $50 discount and also the first two months free by visiting useprophet.com/7investing. This no-upfront-cost deal is only available until July 7th!

What the heck is going on at Wolfspeed?! Originally recorded: May 6, 2025 The WSJ published an article that WOLF is now the most shorted stock in the entire US market. The company's CFO then unexpectedly stepped down. And yet even after what appeared to be the worst-case scenario, recent negotiations have resulted in its stock price doubling within just the past two weeks. I dug into the filings and took a closer look at a Bloomberg terminal with a special situations guru that I called up earlier this week. Here's exactly what's going on with one of the market's most volatile stocks. Are you ready to get started with 7investing, to see all of our active recommendations, our five monthly Best Buys, our buy/hold/sell conviction ratings, and our interactive community forum? If so, your first week is free at: ⁠7investing.com/subscribe

We're bringing back the 7investing podcast! After remaining dormant for a few months, 7investing founder Simon Erickson introduces the new-and-improved show format. That will include: Deeper company-specific insights - including Wolfspeed's financial stability, AMD's leap into the datacenter, Palantir's stock-based compensation, and The Trade Desk's valuation (and that is all just this week!) New guests - including those looking at different sectors of the market such as REITs, crypto, banking, dividends, special situations, and international opportunities Exclusive offers - new partnerships with other investing newsletters and products with exclusive rates for the 7investing audience Livestream formats - recorded live and available for guests to at riverside.fm/studio/7investing-live. I'm excited to get started with our new-and-improved 7investing podcast. See you in the speakers! Are you ready to get started with 7investing, to see all of our active recommendations, our five monthly Best Buys, our buy/hold/sell conviction ratings, and our interactive community forum? If so, your first week is free at: 7investing.com/subscribe

Options guru Jeff Fischer discusses with 7investing how options can be used as a complement to stocks to boost the returns of a long-term investment portfolio. When used responsibly, options can be a fantastic way to boost the overall returns of an investment portfolio. But options are also shorter-term in nature and they are more highly-exposed to risks and uncertainties. So how, exactly, should investors be using them responsibly?  Jeff Fischer has three decades of investing experience. Between writing content for retail investors, co-founding multiple options newsletters, and even managing a hedge fund, he has a wealth of knowledge about investing strategies to generate long term returns. In our recent conversation on March 7, 2025, Jeff discussed how options can be a long-term investor's best friend for boosting returns -- but they also have a few nuances that shouldn't be ignored. Options are best used as a complement to stocks. Jeff describes why he's often writing puts to generate income when he wants to buy a stock at a particular price and writing calls when he's willing to sell a stock for a certain price. We also discussed how investing in options can be slightly different than investing in stocks. Due to their shorter-term nature, options are more exposed to the behavior of the stock market and are more heavily influenced by its current mood of optimism or pessimism. While technical factors do play a role, options strategies should still be built upon fundamental research and valuation. Jeff then described the tradeoff between an option's intrinsic value and its time value. When selling options, you get paid the upfront; and you can later buy it back in the future to close out the contract. Jeff typically looks to close out options positions he has written if they've reached 80% or more of the 's total value -- meaning there's less than 20% of the initial left on the contract. We then discussed the difference between retail and institutional investors. Retail investors have the freedom to invest anywhere they would like, but institutions prefer much more predictability and credibility. When retirement funds are at stake, institutional investors are looking for their fund managers to reliably execute on the strategy they were created to accomplish. In the outro, Jeff offered the sectors and stocks that he most enjoys to invest in. During his 30 year career, he's mostly preferred software companies like Alphabet and Meta Platforms. He also mentioned Airbnb as a most recent opportunity investors might want to consider. To have our investing insights delivered to your Inbox every week, please our free 7investing newsletter today.

Crocs is a very inexpensive stock right now, which could represent an excellent value investment opportunity. Crocs is a global shoe retailer whose comfortable and inexpensive footwear generates $4 billion in annual sales. Its core Crocs brand is growing 17% internationally and 8% direct-to-consumer. Q3 sales got a boost from "Mini-Crocs" being included in McDonald's $MCD Happy Meals and "Batman Crocs" being sold through a recent partnership with DC Comics (both of which are quite adorable). But its recently-acquired HEYDUDE brand has been struggling. HEYDUDE's sales fell 17% this year, as it's not yet resonating with the younger consumer demographic. Crocs is doubling-down on HEYDUDE's brand by hiring Sydney Sweeney to be the long-term ambassador of its marketing. She's encouraging others to be comfortable in their own shoes, and this feels like a good first step to getting sales back on track. As an investment, Crocs looks very inexpensive. The stock is trading at just 7x earnings and 6.5x free cash flow, but it's generating a 70% return on equity and a 25% return on invested capital. There's a pretty clear disconnect there. Crocs' core business is solid and profitable. Yet the market is pricing it as a fad that's in a permanent decline. If the company's new marketing efforts pay off, this inexpensive stock might be worth snapping your jaws on as one of the stock market's most compelling opportunities. See our complete 7investing coverage on Crocs -- including how well it performs based on the legendary value investor Joel Tillinghast's framework -- at: https://7investing.com/company_name/crocs/…

Taiwan Semiconductor $TSM, the world's largest chipmaking foundry, today just issued the largest CapEx forecast of its company's history.Does this mean the chip industry is finally escaping from its cyclical lows, and is ready for a rebound in 2025? TSMC's 4Q 2024 results showcased a 38% year-over-year increase in revenue and a 57% increase in earnings. Those were good numbers. But there might be even better news on the horizon. Management just approved a 2025 capital budget of between $38 billion and $42 billion. 70% of that is dedicated to "advanced technology production" -- i.e. building new fabs to manufacture the cutting-edge chips demanded by AI. This aggressive CapEx forecast is good news for TSMC and also for the entire semiconductor industry. The company will be spending that 2025 budget on equipment vendors such as $ASML, Applied Materials $AMAT, and Axcelis Technologies $ACLS and also on boatload of ing functions. Meanwhile, creative innovations are also unlocking new opportunities. Taiwan Semi is transitioning the fundamental architecture of its transistors from FinFET to gate-all-around. It's updating the foundation its entire house is built on; changing the physical design of the smallest building blocks of its circuits to more efficient and powerful processors. The next few years will be an exciting time for this industry. The semiconductor renaissance looks well-primed to begin a new chapter. See all of our @7investing coverage on $TSMC -- including our current Conviction Rating on the stock -- at:https://7investing.com/company_name/taiwan-semiconductor-manufacturing-company/

Innovation and regulation are quite often at odds. Technology relentlessly marches onward; yet it also needs to safely serve the common good. This is ever so true in banking. While banking may have traditionally been considered to be a rather conservative industry, its innovation curve has steepened significantly as physical banks have gone digital, digital banks have employed AI for lending, and managed s are embracing cryptocurrencies. Today's 7investing podcast features two banking experts, Caitlin Long and John Maxfield, who share their perspectives on the industry's innovation and offer their insights on: - How crypto-bank Silvergate managed (amazingly) to survive an 80% run on its deposits after the collapse of FTX. - Why overly-restrictive regulations such as excessive capital requirements and limitations on crypto might be soon to change. - What expectations the industry should have of the incoming SEC Chairman Paul Atkins and how he differs from outgoing chair Gary Gensler. - How 'debanking' is unfairly punishing many of the industry's key innovators In the final outro, 7investing CEO Simon Erickson plays a game of "over or under", to hear Caitlin and John's differing insights on a variety of popular companies and topics. This was truly an epic conversation between two banking Wyomingites! Follow @CaitlinLong_ and @MaxfieldonBanks on X/Twitter for even more of their insights. Disclaimer: 7investing's hosts and guests may have positions in the companies or cryptocurrencies discussed on this podcast. Nothing discussed in this program should be considered professional financial advice. To learn more about 7investing, visit our website at 7investing.com.

It's an exciting time to invest in the banking sector. Newly-elected President Donald Trump has promised to relax regulations on banks, which could boost lending volumes. The Federal Reserve has lowered interest rates twice during the past two months, which could make companies more eager to borrow. In response, several publicly-traded financial services companies including Upstart Holdings (Nasdaq: UPST), Affirm Holdings (Nasdaq: AFRM), and SoFi Technologies (Nasdaq: SOFI) have seen their share prices skyrocket and are generating fantastic gains for their investors. But will this momentum continue? What impact will Trump's istration really have on banking? And what, specifically, should those of us investing in banking be watching for? In today's podcast, 7investing CEO Simon Erickson gets the answers to those questions from banking expert John Maxfield. The two discuss why the macro is favorable for banking, yet also a few cautionary things to watch out for at SoFi. Disclaimer: 7investing and its guests may have active positions in the companies mentioned in this podcast. To see all of 7investing's active recommendations, sign up for a 7-day free trial of our service at 7investing.com/subscribe.

Veeva Systems (NYSE: VEEV) is helping pharmaceutical companies create and sell new drugs more efficiently. It's cloud-based software platforms Veeva CRM and Veeva Vault have become industry-standards; deeply embedded with Big Pharma's largest companies. There's an catalyst next year, as Veeva's CRM platform will migrate from being hosted by Salesforce to its own infrastructure. That will unlock opportunities for it to develop new software products -- perhaps even beyond life sciences -- to make the pie larger with its largest customers. As interest rates fall, it's likely new VC funding will flow into smaller biotech companies and will unlock a new SMB revenue stream as well. 7investing CEO Simon Erickson describes both of these catalysts, as well as why he believes the stock is undervalued, in today's 7investing podcast. To see all of our official stock recommendations and our monthly Best Buys, get started with 7investing at ⁠7investing.com/subscribe⁠. Your first week of our hip is entirely free!

The Dutch lithography juggernaut ASML (Nasdaq: ASML) has been one of the semiconductor industry's best performing stocks of the past decade. Yet its high-flying shares have sold off 33% in the past three months, perhaps due to its underwhelming forward guidance that could indicate slowing demand. ASML has looked to Intel (Nasdaq: INTC) for much of its growth this past year. Intel has been all-in on expanding its foundry group and aggressively placed orders for six of ASML's latest-and-greatest EUV machines last year. That was a huge sign of confidence, and ASML's shares shot up 50% during the first half of 2024. Yet now facing a cash-crunch, Intel is delaying its new $30 billion fab and is pushing out many of its previously-expected orders. That caused ASML to pull back on its fiscal year forecast and to suffer the wrath of a displeased and suddenly-very-grumpy market. With ASML regain the confidence of investors? Will Intel be an opportunity or a liability going forward? 7investing CEO Simon Erickson shares his thoughts in today's podcast. Would you like to see all of 7investing's stock market recommendations and monthly Best Buys? Learn more about how you can take our service for a 7-day free trial at 7investing.com/subscribe.

Lululemon (Nasdaq: LULU) has expanded from being a niche yoga retailer to an international fitness super-brand. New CEO Calvin McDonald has tripled its sales in five years and maintained its industry-leading 20% operating margin. Yet recently, perhaps due to concerns of a slowdown in consumer spending or of rising competition, the stock has been selling for a dirt-cheap valuation. Now priced at just 15x its trailing cash flow, it could an inexpensive opportunity for opportunistic investors to consider. Would you like to see our official Conviction Rating on Lululemon - meaning whether we think the stock is a "Strong Buy", "Buy", or "Hold"? See all of 7investing's recommendations, conviction ratings, and coverage by getting started FOR FREE today at ⁠7investing.com/subscribe⁠. Disclaimer: The 7investing podcast should not be considered personalized financial advise. Its host and guests may have positions in the stocks that are mentioned.

Our newest stock recommendation is now live! On the 1st of each month, 7investing issues its newest official recommendation. This is the one stock it feels most confident in adding to its scorecard (which we also track in real-time at 7investing.com/recommendations). What led us to recommend this Large Cap, Moderate Risk, Retail company this month? In today's episode, Simon describes 5 specific metrics that investors should consider when selecting stocks -- especially now that the Fed's cutting rates and we're in a more growth-friendly environment.

Booking Holdings (Nasdaq: BKNG) is one of the most efficient publicly-traded companies in the world, converting 50% of its 2024 revenue into cold, hard cash flow. Furthermore, it's using those operating cash flows in shareholder-friendly ways, such as repurchase large amounts of its stock and a newly-initiated dividend. 7investing CEO Simon Erickson takes a look at the company's second quarter results and discuss several initiatives that could be even better news for investors going forward. To sign up free for 7investing and see our most recent five Best Buys for September, visit 7investing.com/subscribe

7investing's Watch List of New Ideas introduces stocks that we've never formally recommended yet are worth considering as future scorecard additions. You can think of this as our pipeline of new investment opportunities. This month, 7investing CEO Simon Erickson is adding two new two European companies: BE Semiconductor (OTC: BESIY) and Novo Nordisk (NYSE: NVO). He describes why Besi's advanced packaging leadership makes it a natural winner from innovative new chip designs, and why Novo Nordisk is still in the earliest innings of introducing Ozempic as a treatment for obesity. 7investing makes its formal recommendations available through its hip. To see all of our stock market recommendations through a 100% free 7 day trial, today at 7investing.com/subscribe.

Fertility benefits company Progyny's (Nasdaq: PGNY) stock is selling off 33% in today's trading session after announced it's losing its largest customer who ed for 13% of the previous year's revenue. This customer was unnamed, but it's most likely Amazon. Even though Progyny has historically had nearly 100% client retention and receives excellent net promoter scores, this could be a red flag for investors. 7investing CEO Simon Erickson shares his thoughts about the company's previous struggles, the Alabama Supreme Court's recent ruling about IVF embryos, and how investors should think about Progyny's stock going forward.